Turn this list into pipeline.
Biotech Companies in Manchester: 84 Active Firms (2026)
Biotech companies in Manchester develop biological research, diagnostics and therapeutics within the city-region’s life-sciences base.
Buying centres tend to sit around translational research, diagnostics development, laboratory tools, bioprocess support and early therapeutic discovery rather than broad enterprise software-style procurement. Buyers are usually research teams, clinical-development groups, pharmaceutical partners, healthcare laboratories and specialist service providers, with sales shaped by evidence quality, assay performance, validation work and regulatory readiness. Engagements are often narrow and technical: feasibility studies, reagent or platform access, lab-service contracts, collaboration agreements and early development work. The commercial rhythm is therefore closer to scientific procurement and partnered development than high-volume product sales, with lean teams needing credibility across biology, quality systems and clinical governance.
Read more
Manchester has 84 actively trading biotech companies in this list, making it a compact but visible part of the city-region’s life-sciences base. Reported employment totals 371 people, which fits a cohort of small specialist businesses rather than large operating divisions. Only 3 companies report turnover above £5M, so revenue scale appears concentrated in a small upper tier, while 18 firms were incorporated since 2022. That mix points to a market where early discovery, diagnostic validation and specialist laboratory services sit alongside a much thinner layer of commercially mature biopharmaceutical activity.
Biotech activity sits inside the UK life-sciences rule set rather than a Manchester-specific regime. The MHRA sets standards, evaluates new treatments, approves clinical trial applications, assesses marketing authorisations and oversees post-authorisation safety monitoring through pharmacovigilance. Clinical work also has to account for Good Clinical Practice, ethics review and informed consent, so buyers often scrutinise quality systems before commercial terms are finalised. Market access for approved medicines can involve health technology assessment before routine public funding, while sector representation is split across research-based pharmaceutical bodies and biotech trade associations such as the ABPI and BioIndustry Association.
Manchester’s cohort appears weighted towards early-commercial and specialist service activity, with scale more likely to emerge through partnerships than pure standalone product sales. Therapeutics-facing businesses tend to need external clinical, regulatory and capital support before revenues become dependable, while diagnostics and research-tool companies can often reach customers through narrower laboratory channels. Scarcity of revenue-scaled firms may keep acquisition, licensing and university-adjacent collaboration in view. Regulatory expectations are unlikely to loosen, so firms that can pair credible biology with documented quality processes should be better placed, though the path still looks uneven and capital-sensitive.
84
Active firms
2026
18
New since 2022
recent incorporations
3
Above £5M
reported revenue
Key facts
About 3% of the trading cohort reports turnover above £5M (3 of 84 firms) — the rest sits below that revenue band.
21% of the cohort was incorporated since 2022 (18 firms), so a sizeable share is in its first few filing cycles.
The MHRA approves clinical trial applications, assesses marketing authorisations or drug licences, and monitors post-authorisation safety through pharmacovigilance.
Approved medicines may also be reviewed by NICE before routine NHS use, making health technology assessment part of the commercial route for many therapeutic developers.
The Office for Life Sciences estimated that the UK life-sciences industry comprised 6,170 businesses across 7,320 companies in 2023/2024, generating £146.9 billion in turnover.
The biopharmaceutical subsector generated £98.9 billion in turnover in 2023/2024, accounting for 67% of total life-sciences turnover.
BIA reported that the UK biotech sector raised £3.5 billion in equity investment in 2024, with financing concentrated in a small number of large rounds, mainly from US investors.
Top Manchester biotech companies
Develops and commercialises point‑of‑care pharmacogenetic diagnostic systems. Products include the Genedrive molecular testing platform and assays detecting genetic variants such as MT‑RNR1 and…
Serves NHS organisations, hospitals and clinical teams in emergency care, neonatal intensive care and stroke services, alongside healthcare partners adopting point-of-care pharmacogenetic diagnostics.
Location
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsProvides quantitative MRI biomarker and imaging services for pharmaceutical, biotech and medical device clinical trials. Supports study design, site setup, data transfer and quality control, image…
Serves pharmaceutical companies, academic researchers and medical device developers running clinical trials, particularly teams working in respiratory, oncology, inflammation, neuroimaging, liver…
Financial Health
StableStable · -3% CAGR over 4y
Location
Trajectory
3y · 2022–NowFinancial sub-scores
Computed from 3 filingsDevelops small‑molecule drug candidates for immuno‑inflammatory diseases. Uses proprietary molecular design and patient stratification platforms to identify and optimise compounds, advancing…
Serves pharmaceutical and biotechnology companies, including large pharma partners, focused on immuno-inflammatory disease pipelines; also addresses investors and shareholders in life sciences.
Financial Health
DistressedDistressed
Location
Develops small‑molecule drug candidates for immuno‑inflammatory diseases. Uses proprietary molecular design and patient stratification platforms to identify and optimise targets, advancing discovery…
Targets global pharmaceutical and biotechnology partners, such as large pharma licensing teams, in immuno-inflammation and related therapeutic areas; also communicates with shareholders and life…
Location
Discovers and develops small‑molecule drug candidates for immuno‑inflammatory diseases. Uses proprietary molecular design and patient stratification platforms to identify targets and advance…
Serves pharmaceutical and biotech companies through drug discovery partnerships, particularly in immuno-inflammatory medicine development. Also targets investors and shareholders through its…
Location
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops data curation and knowledge graph technology for biopharma research. Aggregates and structures biomedical literature and datasets to identify gene, drug and disease relationships, supporting…
Serves B2B bioinformatics and research teams in biopharma, including pharmaceutical and biotech companies involved in drug discovery, target validation and disease research.
Financial Health
HealthyHealthy · -66% CAGR over 4y
Location
AKL RESEARCH & DEVELOPMENT LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsConducts pharmaceutical research and development focused on treatments for osteoarthritis and other age-related diseases. Develops drug candidates including APPA and carries out preclinical and…
Serves pharmaceutical and healthcare partners focused on osteoarthritis and other age-related diseases, with clinicians and patients in those therapeutic areas as the eventual market.
Financial Health
HealthyHealthy · 0% CAGR over 4y
Location
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops biotechnology treatments for hair loss, including a follicle banking service that stores hair follicles for future use and cell‑based therapies that culture follicle cells for injection into…
Targets hair transplant clinicians and clinics, clinical partners, and male and female patients with androgenic alopecia seeking hair rejuvenation pathways; also addresses investors in biotech…
Financial Health
HealthyHealthy · Growing, Hiring · 4% CAGR over 4y
Location
Ascend Diagnostics Ltd
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDesigns and develops MALDI‑TOF mass spectrometry instruments and software for clinical diagnostic laboratories. Provides platforms for high‑throughput microbial identification and analysis, with…
Serves medical and laboratory staff in high-throughput hospital and clinical diagnostics laboratories, including teams responsible for early diagnosis, microbial testing, patient-data analysis and…
Financial Health
WeakWeak · -14% CAGR over 5y
Location
PANMEDISO INVESTMENTS LIMITED
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsDevelops and supplies medical isotopes and radiopharmaceutical technologies for nuclear medicine. Conducts isotope R&D and production, radiopharmaceutical assembly, and contract manufacturing (CDMO),…
Serves B2B healthcare and life sciences buyers, including radiopharmaceutical manufacturers, hospitals, nuclear medicine clinicians, and research organisations involved in precision diagnostics and…
Financial Health
StableStable
Location
Bright Biotech Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops plant-based biotechnology for producing recombinant proteins using chloroplast expression systems. Manufactures growth factors and related proteins for use in cell culture, biotechnology…
Serves B2B life sciences customers, including cell culture, regenerative medicine and biotech organisations, plus research and production teams requiring growth factors.
Financial Health
StrongStrong · Growing, Hiring · 68% CAGR over 4y
Location
UMAX HEALTH LTD
Trajectory
2y · 2024–NowFinancial Health
Insufficient historyInsufficient history
Location
Trajectory
5y · 2022–NowFinancial sub-scores
Computed from 5 filingsProvides preclinical research models, organoid systems and laboratory analysis services to support drug discovery and development. Services include in vivo and in vitro disease models, imaging,…
Serves pharmaceutical and biotechnology companies, particularly R&D teams working across drug discovery, preclinical development and early clinical pipelines in oncology, GI disease, dermatology and…
Financial Health
DistressedDistressed · -72% CAGR over 4y
Location
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops and commercialises the Phagenyx medical device system, which delivers pharyngeal electrical stimulation to restore swallowing function in patients with post‑stroke dysphagia, enabling…
Sells to hospitals and healthcare providers treating post-stroke dysphagia, including stroke units, ICUs, rehabilitation teams, neurologists and speech-language pathology teams.
Financial Health
StableStable · -61% CAGR over 4y
Location
Ainostics Limited
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops artificial intelligence software for medical diagnostics, analysing clinical imaging and related data to detect and predict neurological conditions such as Alzheimer’s disease, multiple…
Serves healthcare organisations and clinicians involved in neurological diagnosis, plus pharmaceutical and clinical research teams running dementia and neurology drug-development studies.
Financial Health
HealthyHealthy · -55% CAGR over 5y
Location
Apis Assay Technologies
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops molecular diagnostic assays, aptamer reagents, and bioinformatics tools for biotechnology and pharmaceutical companies. Offers custom aptamer development, assay design, contract…
Serves diagnostics teams, biotech and pharmaceutical companies developing molecular assays, IVD products, therapeutics and bioinformatics workflows, particularly in oncology, pharmacogenomics and…
Financial Health
StrongStrong · Hiring · 39% CAGR over 4y
Location
AHMED QAMRUDDIN LIMITED
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
StrongStrong · Hiring · 19% CAGR over 4y
Location
AM DIAGNOSTICS LTD
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsManufactures molecular diagnostic instruments, PCR and RT‑qPCR assay kits for detecting infectious diseases, genetic mutations, sexually transmitted infections and foodborne pathogens. Also supplies…
Serves clinical diagnostic laboratories, healthcare providers, research organisations, veterinary testing providers and food safety laboratories requiring molecular assays, instruments, PCR reagents…
Financial Health
WeakWeak · 0% CAGR over 4y
Location
Imperagen Limited
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsDevelops a digital enzyme engineering platform combining AI modelling, quantum simulation and automated robotics to design, build and test enzyme variants. Provides enzyme optimisation and…
Serves B2B organisations with enzyme needs, particularly R&D teams and companies developing or improving enzymes for market-ready applications.
Financial Health
HealthyHealthy · Hiring · 65% CAGR over 3y
Location
BIO-SHAPE LTD.
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
StrongStrong
Location
QA CONSULTANCY LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsFinancial Health
DistressedDistressed · 0% CAGR over 4y
Location
GENINCODE UK LIMITED
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsFinancial Health
StableStable · 0% CAGR over 3y
Location
Mindrank Technologies Limited
Trajectory
3y · 2022–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
WeakWeak · Hiring · 15% CAGR over 2y
Location
PREVENT BREAST CANCER TRADING COMPANY LIMITED
Trajectory
5y · 2021–NowFinancial Health
Insufficient historyInsufficient history
Location
PLANT ORGANELLE TECHNOLOGIES LIMITED
Trajectory
1y · 2024–NowFinancial Health
Insufficient historyInsufficient history
Location
Deakin Bio-Hybrid Materials Ltd
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
HealthyHealthy · Hiring · 41% CAGR over 2y
Location
PRIMAL HEALTH LTD
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops and supplies consumable oral health products for people and pets. Uses patented SMMRT technology to modulate oral microbiome metabolism, supporting beneficial bacteria while reducing harmful…
Targets consumers and pet owners seeking oral health products, and potential commercial partners or licensees in the human and pet oral-care markets.
Financial Health
DistressedDistressed · -36% CAGR over 4y
Location
SEDA PHARMA DEVELOPMENT SERVICES LTD.
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsProvides pharmaceutical development and clinical pharmacology services for pharmaceutical and biotechnology companies, including formulation development, laboratory testing, pharmacokinetic…
Serves B2B pharmaceutical and biotechnology companies developing drug candidates, from early-stage programmes through clinical development and marketing authorisation.
Financial Health
HealthyHealthy · -62% CAGR over 4y
Location
Chromition Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops diagnostic technologies using Luminspheres fluorescent particles for immunofluorescence imaging and molecular detection. Products include systems for detecting circulating tumour cells in…
Serves healthcare diagnostics organisations, clinical laboratories, pathology teams and life science partners involved in cancer screening, immunofluorescence, HER2 testing and point-of-care genomic…
Financial Health
StrongStrong · Growing, Hiring · 11% CAGR over 4y
Location
HUWEL LTD
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops and manufactures molecular diagnostic products including RT‑PCR test kits, nucleic acid amplification devices, oligonucleotides, enzymes, reagents, extraction kits and laboratory plasticware…
Sells B2B to clinical diagnostic laboratories, hospitals, public health and TB testing programmes, point-of-care providers, and life sciences research teams in diagnostics, therapeutics and vaccine…
Financial Health
StrongStrong · Hiring · 26% CAGR over 4y
Location
LIR THERAPEUTICS LIMITED
Trajectory
1y · 2025–NowDevelops engineered viral vectors for gene therapy using AI modelling and laboratory assays. Focuses on designing adeno-associated virus (AAV) capsids to improve tissue targeting, reduce dosage…
Targets B2B biopharma companies, gene therapy developers and research teams working with AAV or other viral-vector platforms, especially those seeking technical collaborators for preclinical…
Financial Health
Insufficient historyInsufficient history
Location
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops small‑molecule cancer therapeutics that transiently inhibit DNA mismatch repair (MMR) to convert MMR‑proficient tumours into immunotherapy‑responsive states, aiming to expand patient…
Serves oncology clinicians and cancer patients, particularly those with MMR-proficient tumours that are currently unresponsive to immunotherapy.
Financial Health
StrongStrong · Hiring · 19% CAGR over 4y
Location
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops cell‑free regenerative medicine therapies derived from stem cell secretomes. Uses a proprietary platform to produce therapeutic mixtures of extracellular vesicles, miRNA and proteins aimed…
Targets healthcare and life sciences organisations working in regenerative medicine, longevity and degenerative disease, with eventual patient populations affected by tissue degeneration,…
Financial Health
WeakWeak · 0% CAGR over 4y
Location
Centessa Pharmaceuticals
Develops pharmaceutical therapies for neurological and sleep‑wake disorders. Advances an orexin receptor 2 agonist drug programme and uses its LockBody technology platform to design targeted biologic…
Targets patients with sleep-wake, neurological, neurodegenerative and neuropsychiatric disorders, alongside healthcare stakeholders involved in neuroscience drug development and future treatment…
Location
SENSIBLE BIOTECHNOLOGIES LIMITED
Trajectory
2y · 2024–NowFinancial sub-scores
Computed from 2 filingsDevelops cell-based platforms for designing and manufacturing mRNA therapeutics. Uses computational tools and biological systems to produce low‑immunogenicity synthetic mRNA and support development…
Serves biopharma and biotechnology companies developing mRNA therapeutics, including R&D, platform and manufacturing teams seeking cell-based mRNA design and production capabilities.
Financial Health
StrongStrong · Hiring · 37% CAGR over 1y
Location
SUDO BIOSCIENCES LIMITED
Trajectory
4y · 2022–NowFinancial sub-scores
Computed from 4 filingsDevelops small‑molecule medicines for neurological and immune‑mediated inflammatory diseases. Conducts drug discovery and clinical development, including TYK2 inhibitor therapies, using medicinal…
Targets patients with serious neurological and immunological conditions, including multiple sclerosis and immune-mediated inflammatory diseases, alongside specialist clinicians and healthcare systems.
Financial Health
StableStable · -67% CAGR over 3y
Location
HYRIS LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops and supplies molecular testing technology including miniaturised qPCR instruments, cloud-based software and diagnostic assays. Platforms support genetic analysis and data management for…
Serves laboratories, hospitals and clinics in healthcare diagnostics, plus nutraceutical businesses, food manufacturers and agronomists. Also targets kit developers, research and academic…
Financial Health
DistressedDistressed · -69% CAGR over 5y
Location
Evariste Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops small‑molecule therapeutics for cancer using AI and mathematical modelling. Identifies synthetic lethal drug targets and biomarkers and designs drug candidates through machine learning,…
Targets oncology drug development partners and cancer patient populations with high unmet need, including NSCLC, colorectal and ovarian cancer, glioblastoma, AML and DLBCL.
Financial Health
WeakWeak · Hiring · 17% CAGR over 4y
Location
BIOLINK LIMITED
Trajectory
4y · 2023–NowFinancial sub-scores
Computed from 4 filingsDevelops and manufactures bioprocessing equipment and single‑use consumables for the life sciences industry, including bioreactors, cell culture systems, chromatography columns and resins, filtration…
Targets B2B life science and biopharmaceutical organisations, especially R&D, process development and manufacturing teams producing monoclonal antibodies, vaccines, mRNA therapies and other…
Financial Health
DistressedDistressed
Location
EP MEDICAL GROUP LTD
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsFinancial Health
HealthyHealthy · Hiring · 41% CAGR over 2y
Location
UNCHAINED LABS LTD
Trajectory
4y · 2023–NowFinancial sub-scores
Computed from 4 filingsDevelops and manufactures laboratory instruments and automation systems for biologics, gene therapy and nanoparticle research. Products measure protein and nucleic acid concentration, particle size,…
Sells to biologics, gene therapy, cell therapy, genomics and nanoparticle researchers in biotech, pharmaceutical and academic labs, including teams working on antibodies, viral vectors, LNPs,…
Financial Health
DistressedDistressed · -37% CAGR over 3y
Location
PHARMA CONSULTING SERVICES LTD
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsProvides consultancy services to pharmaceutical, biotechnology and medical device companies, supporting drug product development from preclinical evaluation to commercialisation, including R&D…
Serves biotech, pharmaceutical and medical device companies developing human or veterinary health products, including ethical Rx, generics and OTC products.
Financial Health
DistressedDistressed
Location
Gaeta Therapeutics Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsCommercialises immuno‑oncology intellectual property relating to the use of Interleukin‑12 (IL‑12) with checkpoint inhibitor therapies for cancer treatment. Manages a patent portfolio covering…
Sells to pharmaceutical and biotechnology companies developing immuno-oncology cancer therapies, particularly organisations licensing intellectual property for IL-12 and checkpoint blockade…
Financial Health
StrongStrong · Growing · 0% CAGR over 4y
Location
KAIZEN BIOSERVICES LTD.
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsProvides support services for clinical trials and research studies, including study design, patient recruitment, clinical site staffing, kit assembly, sample transport and logistics, nucleic acid…
Serves B2B organisations commissioning or delivering clinical trials and clinical research studies, including research teams needing outsourced operational, logistics, sample handling and quality…
Financial Health
DistressedDistressed · -6% CAGR over 5y
Location
Greyrigge Associates Limited
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsProvides consultancy services to biotechnology and pharmaceutical companies developing biologics and advanced therapies, including gene and cell therapies. Advises on CMC and manufacturing, quality…
Serves B2B biotech and biopharma organisations, from start-ups to multinationals, developing biologics and advanced therapies. Targets bench and board-level stakeholders, including clinical, CMC, QA,…
Financial Health
WeakWeak
Location
Tenpoint Therapeutics
Develops pharmaceutical treatments for age‑related eye conditions including presbyopia, cataracts and geographic atrophy. Conducts research and clinical development of ophthalmic drugs aimed at…
Serves eye care professionals and healthcare providers treating adults with age-related vision conditions, including presbyopia, cataracts and geographic atrophy, with patient-focused information for…
Location
CALAMAT LTD
Trajectory
5y · 2020–NowFinancial sub-scores
Computed from 5 filingsDevelops and supplies laboratory equipment and consumables for microscopy, including slide staining systems for immunohistochemistry and histochemistry, redesigned microscope slides for fluorescence…
Sells to B2B laboratory teams and microscopy users working in immunohistochemistry, immunocytochemistry, histochemistry and fluorescence microscopy, including organisations seeking slide staining and…
Financial Health
HealthyHealthy · Hiring · 5% CAGR over 5y
Location
SCOPE INTERNATIONAL (UK) LIMITED
Trajectory
3y · 2023–NowFinancial sub-scores
Computed from 3 filingsProvides contract research organisation services for pharmaceutical and biotechnology companies, managing clinical trials from Phase I–IV. Services include clinical operations, medical writing,…
Serves pharmaceutical, biotech and advanced therapy developers needing B2B clinical research partners for Phase I–IV studies, particularly in pain, women’s health, respiratory, neurology, infectious…
Financial Health
StrongStrong · Hiring · 18% CAGR over 2y
Location
Centessa Pharmaceuticals
Develops pharmaceutical drugs and biologic technologies, including orexin receptor 2 agonists for sleep‑wake, neurological, neurodegenerative and neuropsychiatric disorders, and antibody‑based…
Serves patients with sleep-wake, neurological, neurodegenerative and neuropsychiatric disorders, with information also aimed at clinical trial participants, healthcare stakeholders and investors.
Location
GENEDATA LIMITED
Trajectory
5y · 2021–NowFinancial sub-scores
Computed from 5 filingsDevelops enterprise software for biopharmaceutical research, development, and manufacturing. Provides tools for assay data analysis, bioprocess development, mass spectrometry analysis, and laboratory…
Serves biopharmaceutical companies and research organizations worldwide, targeting experimental and computational scientists, IT/software teams, and operational excellence leaders working across…
Financial Health
StrongStrong · Hiring · 23% CAGR over 4y
Location
Unlock all 84 leads
Showing 50 of 84 — +34 more with verified decision-maker contacts, live data, and CRM sync.
How Manchester biotech companies work and how to sell to them
What they do
Manchester biotech firms usually monetise intellectual property and laboratory capability rather than seats or generic usage. Revenue tends to come from contract research, assay development, sample testing, reagent or kit supply, platform access, process-development work and licence or collaboration income. Early engagements are often paid pilots or scoped work packages, with larger value deferred into milestones, royalties or repeat lab-service volume once evidence has accumulated. Pricing is typically built around protocol complexity, staff time, materials, validation burden and exclusivity rights. Therapeutics-facing firms may have little recurring revenue before partnership or clinical progress, while diagnostics and tools businesses can move earlier into catalogue, framework or service-line sales.
Who they sell to
Typical buyers are research institutes, clinical laboratories, pharmaceutical R&D groups, contract-development providers, specialist distributors and public healthcare organisations. The decision group often includes principal investigators, heads of translational research, laboratory managers, clinical-development leads, quality or regulatory staff and procurement teams; in smaller firms, founders and finance leads stay close to the process. Sales cycles tend to depend on scientific validation rather than budget approval alone. Low-risk consumables and services may move through direct sales or distributor channels, while diagnostic, clinical or therapeutics-related work often needs evaluation, legal review, quality checks and formal procurement.
What they buy
Most Manchester biotech firms tend to spend on laboratory consumables, analytical services, specialist equipment, outsourced research, regulatory advice, quality management, intellectual-property support and clinical-development services. Digital buying is usually practical: laboratory information management, electronic lab notebooks, document control, sample tracking, data analysis, security, finance, HR, CRM and procurement systems. Recruitment services are relevant when scientific, quality, regulatory or commercial roles need hiring in a narrow labour market. Legal, accounting and tax advisers also matter because collaboration agreements, licence terms, grant reporting, R&D claims and investor due diligence can sit close to day-to-day operations.
Why and how to sell to them
Buying intent often appears when a biotech firm moves from exploratory science into validation, prepares for MHRA-facing work, signs a collaboration, raises capital, hires a quality or commercial lead, or outgrows informal lab processes. Common pressures include reproducibility, sample traceability, documentation, cash runway, partner scrutiny and the need to show credible evidence before larger contracts open. Outbound messages tend to land better when they connect to a specific workflow: reducing manual study administration, improving audit readiness, shortening procurement friction, supporting regulated documentation or helping lean scientific teams handle repeatable commercial work without distracting senior researchers.
How this list is built
Data sources
This list is built from UK Companies House filings, XBRL accounts data, and semantic analysis of each company's public website. Revenue and headcount figures come from the most recent filed accounts; where the company has not filed, values are estimated using a model trained on filed history and peer benchmarks and are labelled as estimates.
Classification
Rather than relying solely on SIC codes, Firmbase classifies each company semantically: the company's website is crawled, an AI model reads what the company actually sells, and the company is placed into the relevant industry and subsectors. SIC codes are used as one signal but not the only one. This means a company that registered under a generic SIC code but pivoted into (for example) fintech is correctly identified as fintech, not as its original SIC category.
Freshness
The underlying company data is refreshed from Companies House continuously; filings appear in the list within days of submission. The curated list ordering is regenerated when the underlying data moves meaningfully (company count changes by more than 5%, a new company enters the top-ranked segment, or the filed-revenue numbers for the top firms change). You can see the last-updated timestamp near the top of the page.
Also in Manchester
Related directories
Frequently asked questions
How many biotech companies are there in the Manchester?↓
What counts as a biotech company in this list?↓
Which are the largest biotech companies in the Manchester?↓
What do biotech companies in the Manchester actually do?↓
How does Manchester biotech compare internationally?↓
How is this list built and how fresh is the data?↓
How big are the typical biotech companies in the Manchester?↓
Are these mostly new or established biotech companies?↓
What SIC codes does this use?↓
What buying signals should I look for?↓
Push these 84 companies into your pipeline.
Find the right decision-makers, see verified company data, and export your list in seconds.